相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Quinazoline and quinazolinone as important medicinal scaffolds: a comparative patent review (2011-2016)
Abdul Hameed et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2018)
Kinase-targeted cancer therapies: progress, challenges and future directions
Khushwant S. Bhullar et al.
MOLECULAR CANCER (2018)
Organic synthesis provides opportunities to transform drug discovery
David C. Blakemore et al.
NATURE CHEMISTRY (2018)
Benzofuran-appended 4-aminoquinazoline hybrids as epidermal growth factor receptor tyrosine kinase inhibitors: synthesis, biological evaluation and molecular docking studies
Malose J. Mphahlele et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2018)
Quinazolinone Derivatives as a Potential Class of Compounds in Malaria Drug Discovery
Mohammed Hussen Bule et al.
INTERNATIONAL JOURNAL OF PHARMACOLOGY (2017)
An insight into the therapeutic potential of quinazoline derivatives as anticancer agents
Shagufta et al.
MEDCHEMCOMM (2017)
Modern advances in heterocyclic chemistry in drug discovery
Alexandria P. Taylor et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2016)
Recent advances in 4-aminoquinazoline based scaffold derivatives targeting EGFR kinases as anticancer agents
Rania S. M. Ismail et al.
FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
Quinazoline pharmacophore in therapeutic medicine
Olayinka Oyewale Ajani et al.
BANGLADESH JOURNAL OF PHARMACOLOGY (2016)
Eph Receptors and Ephrins: Therapeutic Opportunities
Antonio Barquilla et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 55 (2015)
Oxadiazoles as Privileged Motifs for Promising Anticancer Leads: Recent Advances and Future Prospects
Imtiaz Khan et al.
ARCHIV DER PHARMAZIE (2014)
Rings in Drugs
Richard D. Taylor et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
A Novel Concept Acquisition Approach Based on Formal Contexts
Ting Qian et al.
SCIENTIFIC WORLD JOURNAL (2014)
Quinazoline derivatives: synthesis and bioactivities
Dan Wang et al.
CHEMISTRY CENTRAL JOURNAL (2013)
4-Aminoquinazoline Analogs: A Novel Class of Anticancer Agents
Kalpana Singh et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2013)
Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer
Caterina Carmi et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Heterocycles in drugs and drug discovery
A. Gomtsyan
CHEMISTRY OF HETEROCYCLIC COMPOUNDS (2012)
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Kristy J. Gotink et al.
ANGIOGENESIS (2010)
Tumor heterogeneity: Causes and consequences
Andriy Marusyk et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2010)
Cancer systems biology: a network modeling perspective
Pamela K. Kreeger et al.
CARCINOGENESIS (2010)
Eph receptors and ephrins in cancer: bidirectional signalling and beyond
Elena B. Pasquale
NATURE REVIEWS CANCER (2010)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
A. F. Gazdar
ONCOGENE (2009)
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang et al.
NATURE REVIEWS CANCER (2009)
The epidermal growth factor receptor family: Biology driving targeted therapeutics
M. J. Wieduwilt et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2008)
ErbB receptors: new insights on mechanisms and biology
Bryan Linggi et al.
TRENDS IN CELL BIOLOGY (2006)
The epidermal growth factor receptor pathway: A model for targeted therapy
Maurizio Scaltriti et al.
CLINICAL CANCER RESEARCH (2006)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Xuewu Zhang et al.
CELL (2006)
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
M Cully et al.
NATURE REVIEWS CANCER (2006)
Allosteric inhibitors of Bcr-abl-dependent cell proliferation
FJ Adrián et al.
NATURE CHEMICAL BIOLOGY (2006)
Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-α in head and neck cancer cells in vitro and in vivo
F Bruzzese et al.
CLINICAL CANCER RESEARCH (2006)
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
TA Carter et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in lipsomes or ErbB2-targeted immunoliposomes
DC Drummond et al.
CLINICAL CANCER RESEARCH (2005)
A comprehensive pathway map of epidermal growth factor receptor signaling
Kanae Oda et al.
MOLECULAR SYSTEMS BIOLOGY (2005)
Epidermal growth factor receptor tyrosine kinase inhibitors
M Ranson
BRITISH JOURNAL OF CANCER (2004)
Active and inactive conformations of the epidermal growth factor receptor
KM Ferguson
BIOCHEMICAL SOCIETY TRANSACTIONS (2004)
The epidermal growth factor receptor-tyrosine kinase: A promising therapeutic target in solid tumors
CA Ritter et al.
SEMINARS IN ONCOLOGY (2003)
Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor
J Stamos et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The HER-2/neu oncogene in tumors of the gastrointestinal tract
JS Ross et al.
CANCER INVESTIGATION (2001)
The protein tyrosine kinase family of the human genome
DR Robinson et al.
ONCOGENE (2000)
Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
T Schindler et al.
SCIENCE (2000)
分享论文
